Barclays has re-evaluated its stance on AkzoNobel, downgrading the Dutch paints maker from Overweight to Equal Weight and cutting its price target by 32% to €47 from €69. The bank pointed to structural pricing delays, regional exposure that weakens pricing power, and growing balance-sheet risk related to the proposed Axalta merger as the primary drivers behind the decision.
Shares of the company moved lower on the news, down 3.8% at 05:33 ET (09:33 GMT). The stock traded at €51.14 as of March 18, leaving it about 8.1% above the revised target level.
At the centre of Barclays' concern is AkzoNobel's pricing mechanism. Contracts reference backward-looking raw material indices - specifically PPI, TiO2 and freight indices - which create roughly a six-month lag before rising input costs can be reflected in selling prices. That timing mismatch, the broker says, leaves the firm exposed to sustained periods of high oil and feedstock costs.
Barclays highlighted the composition of input costs to explain the sensitivity. Direct energy outlays account for less than 2% of sales, while raw materials make up approximately 50% of total paint production costs, with roughly half of that mix linked to oil. The company itself has previously acknowledged structural pricing weakness; Chief Executive Gregoire Poux Guillaume noted at the company’s April 2023 results that pricing dynamics had been a problem. "In 2021, pricing lagged the inflationary impact resulting in a negative impact of €153 million in our P&L," he said, adding that AkzoNobel recovered €212 million in 2022.
Distribution and regional footprint are additional constraints, according to Barclays. AkzoNobel relies heavily on third-party distributors, particularly in North America, which limits the speed and scope of repricing compared with fully integrated peers. Barclays contrasted this model with Sherwin-Williams, which can implement price increases rapidly across an estimated 6,000 company-owned stores within days.
Asia is also a material source of vulnerability. AkzoNobel’s Asia assets represent approximately 28% of total exposure, the second-highest level among diversified European chemicals peers, Barclays said. The bank noted structural differences in customer sourcing: in China, customers typically multi-source from two to three suppliers, versus a common single-supplier relationship in the United States. That multi-sourcing culture in China structurally limits pricing power during inflationary episodes.
On the balance-sheet front, Barclays drew attention to recent refinancing and potential cash distributions tied to the Axalta deal. AkzoNobel refinanced a €500 million bond that matured April 8, originally issued at a 1.125% coupon, by locking in new debt at approximately 4-4.6%. That refinancing occurred alongside the potential for a €2.5 billion special dividend linked to completion of the proposed Axalta transaction.
Barclays modelled the pro-forma combined group's leverage and found net debt to EBITDA of roughly 2.5-3.1x, with the lower end of that range achievable only if $600 million of synergies are fully delivered. Barclays described that synergy target as ambitious, observing it implies synergies equal to about 3.5% of pro-forma revenue compared with less than 2% delivered in comparable transactions cited by the bank, including Sherwin-Williams/Valspar and PPG/SigmaKalon.
Reflecting these concerns, Barclays trimmed its 2026 adjusted EBITDA forecast to €1.407 billion, around 4.3% below consensus and beneath AkzoNobel’s own guidance of more than €1.47 billion. The broker's adjusted EPS estimates are €3.92 for 2026, €4.19 for 2027 and €4.29 for 2028. Valuation assumptions include an 11.2x one-year forward price-to-earnings multiple, with scenario cases of €84 to the upside and €42 to the downside.
Despite the downgrade, Barclays stopped short of a full Underweight rating. The brokerage noted AkzoNobel's historical capacity for meaningful margin recovery once raw-material inflation reverses, pointing out the company achieved roughly 390 basis points of margin expansion in 2023. Barclays nevertheless retains a cautious industry view, describing the European Chemicals and Ingredients sector outlook as Negative.
Bottom line: Barclays' downgrade reflects a combination of structural pricing lag, regional exposure that limits repricing flexibility, and balance-sheet pressure in the context of the proposed Axalta transaction. The bank has reduced earnings forecasts and set a lower price target, while acknowledging the company’s past ability to recover margins when input-cost pressures abate.